Instem has accelerated its payment of the Logos Technologies earnout, in a move that suggests performance in both businesses is strong. The mid-2013 acquisition of Logos and its ALPHADAS product suite marked a bold but potentially well-timed move into the early phase clinical market. It expanded the group’s portfolio of study management software (like the preclinical flagship Provantis product), but the entire clinical space is larger and has significant additional potential. This note describes the likely rationale behind the acceleration of the process, and more generally the scale of the opportunity.